<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826266</url>
  </required_header>
  <id_info>
    <org_study_id>PER977-01-001</org_study_id>
    <secondary_id>PER977-01-001</secondary_id>
    <nct_id>NCT01826266</nct_id>
  </id_info>
  <brief_title>Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban</brief_title>
  <acronym>PER977-P1</acronym>
  <official_title>Phase I Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AMAG Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PER977 monotherapy and co-administration following 60 mg edoxaban will have an acceptable&#xD;
      safety and tolerability profile with no impact on pro-coagulant biomarkers. A dose of PER977&#xD;
      that reverses the effects of edoxaban on the pharmacodynamic (PD) biomarkers (point of care&#xD;
      prothrombin time [PoC-PT]), and/or secondary biomarkers (thromboelastography reaction time&#xD;
      [TEG-R]) will be identified.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Normal subjects will be dosed with PER977 or placebo alone and 1 week later, they will be&#xD;
      given a single dose of edoxaban followed in 3 hours by a single IV dose of PER977. The&#xD;
      purpose is to show safety and tolerability of PER977 alone and when combined with a NOAC&#xD;
      (edoxaban). The study will also provide some insight into the doses that may be required to&#xD;
      reverse a steady state edoxaban.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety, tolerability, and plasma and urinary pharmacokinetics (PK) of a range of single intravenous (IV) doses of PER977</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic assessment</measure>
    <time_frame>2 days</time_frame>
    <description>To determine the effect of escalating doses of PER977 on the reversal of edoxaban-induced anticoagulation</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Anticoagulant Reversal</condition>
  <condition>Reversal of Edoxaban Induced Anticoagulation</condition>
  <arm_group>
    <arm_group_label>PER977-Dose 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PER977-Dose 7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Titration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PER977, Placebo</intervention_name>
    <arm_group_label>PER977-Dose 1</arm_group_label>
    <arm_group_label>PER977-Dose 2</arm_group_label>
    <arm_group_label>PER977-Dose 3</arm_group_label>
    <arm_group_label>PER977-Dose 4</arm_group_label>
    <arm_group_label>PER977-Dose 5</arm_group_label>
    <arm_group_label>PER977-Dose 6</arm_group_label>
    <arm_group_label>PER977-Dose 7</arm_group_label>
    <other_name>ciraparantag</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults age 18 to 45 years, inclusive&#xD;
&#xD;
          2. Laboratory values (chemistry, complete blood count coagulation assessments) and&#xD;
             urinalysis performed during screening up to 21 days prior to administration of study&#xD;
             treatment are within normal limits.&#xD;
&#xD;
          3. No clinically significant findings on 12-lead electrocardiogram (ECG) performed during&#xD;
             screening.&#xD;
&#xD;
          4. Body mass index (BMI) 18 to ≤32 kg/m2, inclusive&#xD;
&#xD;
          5. Male subjects agree to use appropriate contraception (i.e., double barrier&#xD;
             contraception such as a latex condom with spermicide with a female partner of&#xD;
             child-bearing potential (a non-menopausal female who has not had one of the following:&#xD;
             a) a hysterectomy (with or without oophorectomy), b) a bilateral oophorectomy without&#xD;
             hysterectomy, or c) a medically documented ovarian failure) using a diaphragm or&#xD;
             cervical cap or single barrier contraception if the female partner is using an&#xD;
             intrauterine device or hormonal contraceptives or is sterilized; no barrier is&#xD;
             required if the female partner has had a hysterectomy) when engaging in sexual&#xD;
             activity during the course of the study. Moreover, male subjects should not donate&#xD;
             sperm or attempt to impregnate a partner during the course of the study and for a&#xD;
             period of 12 weeks following discharge from the study.&#xD;
&#xD;
          6. Female subjects of non-childbearing potential (a menopausal female with the above 3&#xD;
             definitions for menopause) agree to use two forms of non-hormonal contraceptive (e.g.&#xD;
             barrier methods [condom or diaphragm]) or intrauterine device for the duration of the&#xD;
             study and for 30 days following the completion of the study. Women are considered&#xD;
             post-menopausal and not of child bearing potential if they have had 12 months of&#xD;
             natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age&#xD;
             appropriate, history of vasomotor symptoms) or have had surgical bilateral&#xD;
             oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago.&#xD;
             In the case of oophorectomy alone, only when the reproductive status of the woman has&#xD;
             been confirmed by follow up hormone level assessment is she considered not of child&#xD;
             bearing potential.&#xD;
&#xD;
          7. Nonsmokers or nonusers of nicotine containing products within 3 months of dosing&#xD;
             (occasional use of tobacco products within 30 days of dosing will be considered on a&#xD;
             case-by-case basis)&#xD;
&#xD;
          8. Subjects must understand and agree to comply with the requirements of the study and&#xD;
             they must be willing to sign the informed consent form indicating voluntary consent to&#xD;
             participate in the study prior to initiation of screening or study related activities.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or current evidence of clinically significant cardiac, hepatic, renal,&#xD;
             pulmonary, endocrine, neurologic, infectious, gastrointestinal, hematologic, or&#xD;
             oncologic disease as determined by screening history, physical examination, laboratory&#xD;
             test results or 12-lead ECG. History or current evidence of liver function tests&#xD;
             greater than the upper limit of normal. History or current evidence of QTc Fridericia&#xD;
             (QTcF) greater than normal (430±10 msec for males or 450±10 msec for females; average&#xD;
             of three measurements).&#xD;
&#xD;
          2. History of unexplained syncope&#xD;
&#xD;
          3. Use of any drugs or substances known to be strong inhibitors or strong inducers of&#xD;
             CYP3A4/5 transporters of p-glycoprotein within 28 days prior to the first dosing&#xD;
&#xD;
          4. History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery&#xD;
             within six months prior to screening&#xD;
&#xD;
          5. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena,&#xD;
             rectal bleeding) or bleeding from hemorrhoids within six months prior to screening&#xD;
&#xD;
          6. History of minor bleeding episodes such as epistaxis, rectal or hemorrhoidal bleeding&#xD;
             (spots of blood on toilet paper) or gingival bleeding within 3 months prior to&#xD;
             screening&#xD;
&#xD;
          7. Personal or family history of clotting disorder or abnormality, excessive bleeding,&#xD;
             thrombovascular disease or any hematologic disorder involving platelets or clotting&#xD;
             abnormalities or any condition requiring treatment with transfusions, anticoagulants&#xD;
             or platelet inhibitors&#xD;
&#xD;
          8. Females with a history of dysfunctional uterine bleeding, including history of&#xD;
             menorrhagia (heavy menstrual bleeding), metrorrhagia or polymenorrhea or current use&#xD;
             of hormonal contraceptives.&#xD;
&#xD;
          9. Pregnant or breast-feeding&#xD;
&#xD;
         10. Male subjects with a history of hormone therapy within the 3 months prior to screening&#xD;
&#xD;
         11. Administration of any blood product or anticoagulant within 3 months prior to study&#xD;
             entry or any non-steroidal anti-inflammatory drug or cyclooxygenase inhibitor within 2&#xD;
             weeks prior to screening&#xD;
&#xD;
         12. Taking any type of chronic medication within the 4 weeks prior to study entry&#xD;
&#xD;
         13. Positive serologic test for human immunodeficiency virus (HIV), Hepatitis C virus&#xD;
             (HCV), or Hepatitis B surface antigen (HBsa)&#xD;
&#xD;
         14. Use of any of the following medications in the 4 weeks prior to study entry: rifampin,&#xD;
             dronedarone, ketoconazole, verapamil, amiodarone, quinidine, clopidogrel, oral&#xD;
             anticoagulants, or other agent known to interact with edoxaban&#xD;
&#xD;
         15. Donation of blood or blood products within 56 days prior to enrollment&#xD;
&#xD;
         16. Participation in any study with an investigational compound or device within 30 days&#xD;
             prior to signing informed consent&#xD;
&#xD;
         17. Active drug, alcohol or nicotine use or dependence or any condition that, in the&#xD;
             opinion of the Investigator, would interfere with adherence to study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Noveck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research, Unit 200</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 3, 2013</study_first_submitted>
  <study_first_submitted_qc>April 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PER977</keyword>
  <keyword>Activated partial thromboplastin time</keyword>
  <keyword>Assessment</keyword>
  <keyword>D-dimer</keyword>
  <keyword>Enrollment</keyword>
  <keyword>Investigational drug</keyword>
  <keyword>Investigational treatment</keyword>
  <keyword>Period</keyword>
  <keyword>Premature subject withdrawal</keyword>
  <keyword>Prothrombin time</keyword>
  <keyword>Randomization number</keyword>
  <keyword>Study discontinuation</keyword>
  <keyword>Study drug</keyword>
  <keyword>Subject number</keyword>
  <keyword>Study treatment</keyword>
  <keyword>Thromboelastography-reaction time</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

